Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib with Rituximab and Methotrexate in SCNSL
NCT05398224Phase 2Unknown
- Sponsor
- Peking University
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in secondary central nervous system lymphoma (SCNSL), sponsored by Peking University. Primary endpoint: Progression Free Survival at 1 year. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT05398224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398224.